Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Pulmatrix Inc.
DescriptionDry powder formulation of an inhaled a kinase inhibitor using Pulmatrix's iSPERSE drug delivery platform
Molecular Target
Mechanism of ActionKinase inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentDiscovery
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today